Actively Recruiting
Riluzole in Patients With Spinocerebellar Ataxia Type 7
Led by S. Andrea Hospital · Updated on 2024-12-02
34
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.
CONDITIONS
Official Title
Riluzole in Patients With Spinocerebellar Ataxia Type 7
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Positive genetic test for SCA7
- Age 7 years or older
You will not qualify if you...
- Cardiac arrhythmias
- Haematologic diseases
- Liver diseases with elevated liver enzymes or bilirubin above 1.75 times the normal limit
- Pregnancy (women of childbearing potential must agree to use contraception)
- Breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Neurological Unit, S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome
Rome, Italy, 00139
Actively Recruiting
Research Team
S
Silvia Romano, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here